mercoledì, 22 maggio 2024
30 Gennaio 2018

FDA approves new treatment for certain digestive tract cancers

January 26, 2018 – The U.S. Food and Drug Administration today approved Lutetium Lu 177 dotatate for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutetium Lu 177 dotatate is indicated for adult patients with somatostatin receptor-positive GEP-NETs … (leggi tutto)